PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization for acoramidis, under the brand name BEYONTTRA, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer.

“The ATTRibute-CM results represent a major advance for patients with ATTR-CM, who often face an earlier and more aggressive course of disease,” said Fábio Fernandes, M.D., Ph.D., Director at the Heart Institute of the Clinical Hospital of the University of São Paulo Medical School (HCFMUSP), and investigator in the trial. “For too long, this community has lived with limited options and delayed recognition of their condition. Seeing a therapy like acoramidis deliver significant reductions in cardiovascular-related hospitalizations, improvements in survival, and preservation of functional capacity and quality of life is profoundly encouraging. These results signal a transformative shift in how we can care for patients across Brazil.”